By Chad Terhune
(Reuters) -Just one in 4 U.S. sufferers prescribed Novo Nordisk’s Wegovy or Ozempic for weight reduction had been nonetheless taking the favored drugs two years later, in keeping with an evaluation of U.S. pharmacy claims offered to Reuters that additionally confirmed a gentle decline in use over time.
The evaluation doesn’t embody particulars about why sufferers give up. But it surely does supply an extended view on the real-world experiences of sufferers taking the medicine than earlier analysis that studied use over a yr or much less.
Proof that many individuals could cease utilizing the weight-loss therapies not lengthy after beginning is influencing a debate over their price to sufferers, employers and authorities well being plans.
Wegovy and comparable medicines, which belong to a category of medication generally known as GLP-1 receptor agonists, can price greater than $1,000 per thirty days, and should require prolonged use to yield significant advantages.
Their U.S. costs have drawn fireplace lately from President Joe Biden and different public officers, who stated such medicine may price the nation $411 billion per yr if solely half of adults with weight problems used them. That’s $5 billion greater than Individuals spent on all prescribed drugs in 2022.
“GLP-1s for all is not price efficient,” stated Dr. Rekha Kumar, an weight problems specialist at New York Presbyterian-Weill Cornell Medical Middle and chief medical officer at Discovered, an internet weight-loss program. “Folks need to present weight problems care to their workers, however they need to do it in a manner that doesn’t bankrupt them.”
Prime Therapeutics and Magellan Rx Administration, a pharmacy advantages supervisor, reviewed pharmacy and medical claims knowledge for 3,364 folks with business well being plans that cowl GLP-1 medicine. That they had all obtained new prescriptions between January and December 2021, and had a prognosis of weight problems or a physique mass index of 30 or increased.
The PBM excluded sufferers utilizing the medicine for kind 2 diabetes, for which these medicines had been initially developed. The imply age of sufferers included within the evaluation was 46.5 and 81% had been feminine.
Final yr, Prime revealed knowledge that discovered 32% of sufferers had been nonetheless taking a GLP-1 drugs for weight reduction 12 months after their preliminary prescription. The brand new knowledge reveals that general, for all of the medicine included within the examine, solely about 15% had been nonetheless on their treatment after two years.
For Wegovy, 24.1% of sufferers continued with remedy over two years with no hole of 60 days or extra, down from 36% who had stayed on the drug for a full yr. With Ozempic, which has the identical energetic ingredient as Wegovy – semaglutide – 22.2% of sufferers stored filling their prescriptions at two years, down from 47.1% who had used it for one yr.
Older GLP-1 medicine fared worse. At two years, solely 7.4% of sufferers had been nonetheless taking Novo’s Saxenda, a much less efficient weight-loss drug that some well being plans require sufferers strive earlier than newer GLPs like Wegovy or Eli Lilly (NYSE:)’s Zepbound.
Within the evaluation, 45% of sufferers had been taking Ozempic or Wegovy. Others had been taking Saxenda or Victoza, that are each liraglutide, Rybelsus, an oral model of semaglutide, or Lilly’s Trulicity (dulaglutide).
The evaluation additionally discovered that 26% of sufferers switched GLP-1 medicine throughout remedy, maybe reflecting shortages or modifications in insurance coverage protection, in keeping with Dr. Patrick Gleason, assistant vice chairman for well being outcomes at Prime/MRx and a co-author of the evaluation.
Each Novo and Lilly have been unable to maintain up with unprecedented demand for the brand new medicines.
‘NO ONE REALLY KNOWS’
Novo Nordisk (NYSE:) in a press release cited a number of limitations to the evaluation. It famous that Wegovy wasn’t launched till June 2021, the center of the examine interval, and wasn’t instantly lined by insurance coverage. And Ozempic is not permitted for weight reduction, which may have an effect on sufferers’ protection and persistence with remedy, the Danish drugmaker stated.
The corporate stated it “doesn’t imagine these knowledge are enough to attract conclusions about general affected person adherence and persistence to varied GLP-1 medicines, together with our therapies.”
The newer GLP-1s in medical trials helped folks lose greater than 15% of their physique weight by suppressing urge for food and selling a sense of fullness. They’re being examined for a bunch of different well being advantages that might enhance insurance coverage protection.
Wegovy in March received U.S. approval for decreasing the danger of strokes and coronary heart assaults in obese and overweight adults.
The evaluation did not monitor long-term use of Lilly’s Mounjaro and Zepbound, which launched after the examine’s place to begin. Eli Lilly declined to touch upon the general findings.
Prime/MRx didn’t ask sufferers why their prescriptions stopped. Gleason stated it is doubtless a mixture of unintended effects similar to nausea and vomiting, out-of-pocket prices not lined by insurance coverage and provide shortages.
Some sufferers could determine to cease the treatment after efficiently dropping pounds, medical doctors stated. Different research have proven that the majority sufferers who give up their GLP-1 medicine normally regain many of the weight.
“Nobody actually is aware of how lengthy try to be on these drugs,” stated Dr. Walid Gellad, a professor of drugs on the College of Pittsburgh who research treatment adherence.
Some clinics and telehealth providers aren’t screening sufferers correctly or offering enough teaching on diet and train alongside the drug, Kumar stated, resulting in poor outcomes and sufferers giving up.
Prime/MRx is owned by 19 U.S. Blue Cross and Blue Defend medical insurance plans and manages pharmacy advantages for about 38 million folks.
Dr. David Lassen, the PBM’s chief medical officer, referred to as the regular drop in persistence two years into remedy regarding.
“It’s not leveling off however getting barely worse,” he stated. “It’s actually about sustainability of weight reduction in an effort to obtain long-term outcomes.”
